Clinical Investigation Shows Herb-Pharma's ViroStop Spray Effective in Reducing Impact of Covid-19
21.9.2021 13:00:00 EEST | Business Wire | Press release
A recent clinical study has shown that the ViroStop anti-viral spray from Swiss company, Herb-Pharma is effective in reducing the impact of Covid-19 for patients with mild to moderate symptoms.
The key benefits were a 60% reduction in viral shedding after using the treatment and a reduction in the severity of clinical respiratory symptoms. The study supports the findings of earlier in-vitro tests where its mix of polyphenols inhibited the growth of the virus in cell cultures.
The study included 170 PCR confirmed SARS-CoV-2 patients at the Complex Medical Clinic in Budapest, Hungary between January 15th, and May 31st, 2021. The volunteers all had mild to moderate respiratory symptoms, having tested positive in PCR tests for Covid-19 at the start of the study, and their symptoms were monitored over 12 days.
Of the 170 volunteers, 86 received a nasopharyngeal spray, the patented ViroStop solution, which contains a mixture of Cistus Creticus and other polyphenol-rich ingredients. Polyphenols when attached to viral protein, mechanically inhibit the workings of the protein, and thus stop the virus from entering the cell. The rest of the 84 patients remained in the control group and were not given the ViroStop solution. Each patient’s symptoms were checked every two days for 12 days.
At the end of the study the level of viral shedding was checked by PCR tests. Those patients who had used the ViroStop spray from the first day after testing positive, showed an almost 60% reduction in viral shedding on day 12, compared to the control group. The study showed that the severity of respiratory clinical symptoms was also reduced in those who used ViroStop spray.
A reduction was also noted in gastrointestinal symptoms compared to the control group. Recent research has shown that a key factor in the spread of the virus is its ability to also multiply in the gastrointestinal tract.
Dr István Jankovics, whose team ran the study commented, “The primary treatment for Covid 19 is, of course, vaccination, however this study means that the use of the ViroStop spray significantly inhibits the amount of SARS CoV-2 in the upper respiratory tract, thus providing an opportunity for the infected person to develop a specific immune response.”
ViroStop is a non-prescription treatment, made from natural ingredients and can be taken safely by children as young as three. Furthermore, at the time of the study, at least three variants of the virus were present in Hungary, so it is reasonable to assume that the solution and the action of polyphenols is effective against all known mutations of Covid-19.
Issued on behalf of:
Herb-Pharma AG
Waldmannstrasse 6,
8001 Zurich, Switzerland
Company email: home@herb-pharma.com
For more information visit: https://www.virostop.info/
Company website: https://www.fytofontana.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005309/en/
Contact information
For media enquiries:
virostop@contextpr.co.uk
+44(0)300 124 6100
Eleanor Smith / Eleanor.smith@contextpr.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Allianz Achieves Record Operating Profit of 17.4 Billion Euros – Excellent Start to New Strategic Cycle26.2.2026 08:16:00 EET | Press release
12M 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225107874/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Excellent momentum and record operating profitTotal business volume rises 8.11 percent and reaches 186.9 billion euros with contributions from all segments Operating profit increases 8.4 percent to 17.4 billion euros, our highest operating profit ever Shareholders’ core net income advances 10.9 percent to 11.1 billion euros Core earnings per share (EPS) grow 12.5 percent and reach 28.61 euros Core return on equity (RoE) reaches an excellent level of 18.1 percent Solvency IIratio2 increases 10 percentage points to 218 percent supported by excellent capital generation 4Q 2025 Diversified growth and double-digit increase in shareholders’ core net incomeTotal business volume rises 6.5 1 percent with contributions from all segments Operating profit increases 3.0 percent to 4.3 billion euros, driven by excell
Tigo Energy Showcases Real-time Active Commissioning Software at KEY 2026 Expo26.2.2026 07:00:00 EET | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo,” “Company”), a leading provider of intelligent solar and energy software solutions, today announced the Company’s presence as an exhibitor at the 2026 KEY – The Energy Transition Expo in Rimini, Italy, where Tigo will preview the new active commissioning software. From basic solar-only installations to advanced solar-plus-storage configurations, the system supports installers throughout the entire jobsite workflow via the Tigo EI App, delivering on-site guidance, real-time progress visibility, and clear verification of every required step to help reduce delays, truck rolls, and commissioning uncertainty. At KEY 2026, Tigo will also showcase the latest expansions to the Installer Loyalty Program, including new eligibility tiers and segments, enhanced data support for installers, and upgraded co-branding opportunities. As Italy prepares for a new phase of structural growth in its solar market, with an estimated 6 to 8 GW of new capacity additions
Indra Group Exceeds All Its Guidances in 2025 and Sets Even More Ambitious Guidances for 2026 Than Those Set Out in Its 'Leading the Future' Strategic Plan26.2.2026 00:08:00 EET | Press release
Indra Group (MAD:IDR): • The fourth-quarter order intake in 2025 totaled €8.329 billion, raising thefull-year backlog to €16.083 billion (122% more than in 2024). The Defence backlog stood at €11.336 billion, far exceeding the target of more than €10 billion set for 2026. • Revenues increased by 13% in 2025 with respect to 2024, with double-digit year-on-year rises in Defence, ATM and Mobility Revenues recorded a 28% year-on-year rise in the final quarter of the year • EBITDA and EBIT recorded respective 17% and 18% year-on-year increases, while Indra Group’s profitability improved by half a percentage point, with the EBIT margin standing at 9.5% in 2025. The EBIT margin in the fourth quarter stood at 10.8%. • The net result totaled €436 M, a figure 57% higher than in 2024, while the cashgeneration (FCF) stood at €364 in 2025, set against €328 M in 2024. • R&D and innovation investment reached €472 million in fiscal year 2025. • The company sets itself financial guidances for 2026 that
OLX Launches Agentic AI Products to Transform Property Search and Car Sales at CLAIM AI in Lisbon25.2.2026 16:33:00 EET | Press release
OLX Group, the largest and fastest growing platform for vertical transactions in Europe and South Africa, today unveiled two new Agentic AI-powered products at CLAIM AI, its invite-only Lisbon conference for marketplace innovators. Launching in key OLX markets, CompassGPT introduces a conversational assistant to real estate search, while AutoIQ provides dealers with automotive intelligence, powering dealership performance and providing smarter sales tools, making OLX the only classifieds platform with Agents supporting both the demand and supply sides of digital marketplaces. "At OLX, we are not waiting for the future of AI – we are creating it. Our AI-first infrastructure, built since 2018 and combined with our proprietary data loop, allows us to deliver industry-defining agentic AI solutions that generic models simply cannot match,” said Christian Gisy, CEO of OLX. “CompassGPT and AutoIQ demonstrate how we're turning vision into measurable value for real estate agents, dealers and bu
Andersen Global Broadens Capabilities in Canada with Addition of Law Firm Parlee McLaws25.2.2026 16:30:00 EET | Press release
Andersen Global expands its presence in Canada with the addition of collaborating firm Parlee McLaws LLP, adding complementary legal capabilities to its existing platform in the country. Founded in 1883, Parlee McLaws provides a broad range of legal services including corporate and commercial law, securities law, litigation, real estate, labor and employment, intellectual property, energy, insolvency, administrative law, and online brand protection. With offices in Edmonton and Calgary, the firm has built a reputation for delivering practical, client-focused solutions tailored to the needs of businesses and individuals across industries. “Our collaboration with Andersen Global provides our clients with access to a broader suite of global resources while maintaining the personalized service and deep regional knowledge that define our firm,” said Jerri L. Cairns, managing director of Parlee McLaws. “We look forward to working together to deliver integrated solutions that address the comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
